In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

WuXi NextCODE raises $200mm in Series C financing

Executive Summary

WuXi NextCODE Genomics (genomic data platform) raised $200mm in its Series C financing round. The round included participation from a consortium led by the Ireland Strategic Fund ($70mm), along with existing investors Temasek, Yunfeng Capital and Sequoia Capital. WuXi plans to use the proceeds to expand operations at Genomics Medicine Ireland (GMI), which the company recently acquired, and to speed up enrollment and sequencing of the entire genome of 400k people across Ireland for use in precision medicine. To date, WuXi has raised over $450mm in venture funding including a $240mm Series B round last year.

Deal Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • Services
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies